Search results for "Clero"

showing 10 items of 2052 documents

Transcranial magnetic resonance-guided focused ultrasound thalamotomy as a safe treatment option in multiple sclerosis patients with essential tremor

2020

Transcranial magnetic resonance-guided focused ultrasound is a recently introduced incisionless treating option for essential tremor and tremor-dominant idiopathic Parkinson disease. There is preliminary evidence that it may result in a promising effective treatment option for other movement disorders too. Here, we report on two patients with multiple sclerosis with medication refractory debilitating essential tremor comorbidity who successfully underwent unilateral Vim tcMRgFUS thalamotomy for tremor control. Patients' clinical condition and expanded disability status scale scores showed no changes during the 1-year follow-up period with no evidence of multiple sclerosis activity or progre…

medicine.medical_specialtyNeurologyMovement disordersMagnetic Resonance SpectroscopyMultiple Sclerosismedicine.medical_treatmentEssential TremorDermatologyStereotaxic Techniques03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationThalamusMultiple SclerosimedicineHumansInterventional Magnetic Resonance Imaging030212 general & internal medicineExpanded Disability Status Scalemedicine.diagnostic_testEssential tremorThalamotomybusiness.industrySettore MED/27 - NeurochirurgiaMultiple sclerosisSettore MED/37 - NeuroradiologiaMagnetic resonance imagingGeneral Medicinemedicine.diseaseMagnetic Resonance Imagingnervous system diseasesPsychiatry and Mental healthTreatment OutcomeStereotaxic techniqueHigh-Intensity Focused Ultrasound AblationSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptombusinessSettore MED/36 - Diagnostica Per Immagini E Radioterapia030217 neurology & neurosurgery
researchProduct

Disability assessment using Google Maps.

2021

Objectives To evaluate the concordance between Google Maps® application (GM®) and clinical practice measurements of ambulatory function (e.g., Ambulation Score (AS) and respective Expanded Disability Status Scale (EDSS)) in people with multiple sclerosis (pwMS). Materials and methods This is a cross-sectional multicenter study. AS and EDSS were calculated using GM® and routine clinical methods; the correspondence between the two methods was assessed. A multinomial logistic model is investigated which demographic (age, sex) and clinical features (e.g., disease subtype, fatigue, depression) might have influenced discrepancies between the two methods. Results Two hundred forty-three pwMS were …

medicine.medical_specialtyNeurologyMultiple SclerosisConcordanceAmbulatory disordersDermatology03 medical and health sciencesDisability Evaluation0302 clinical medicineInternal medicinemedicineGoogle MapsHumans030212 general & internal medicineDepression (differential diagnoses)Ambulatory disorderFatigueNeuroradiologyExpanded Disability Status Scalebusiness.industryGeneral MedicineOdds ratioConfidence intervalSearch EnginePsychiatry and Mental healthCross-Sectional StudiesAmbulatorye-HealthOriginal ArticleNeurology (clinical)businessDigital health030217 neurology & neurosurgeryNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyReferences
researchProduct

Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.

2006

This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up per…

medicine.medical_specialtyNeurologyMultiple SclerosisDermatologySeverity of Illness IndexInterferon beta • Multiple sclerosis • Phase IV • Odds ratioInternal medicineSeverity of illnessmedicineConfidence IntervalsHumansImmunologic FactorsMultiple sclerosiNeuroradiologyAnalysis of Variancemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingGeneral MedicineOdds ratioInterferon-betaOdds ratiomedicine.diseaseInterferon betaMagnetic Resonance ImagingConfidence intervalPsychiatry and Mental healthItalyPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)NeurosurgeryPhase IVbusinessFollow-Up Studies
researchProduct

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

2021

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to i…

medicine.medical_specialtyNeurologyMultiple SclerosisToluidinesHydroxybutyratesOral drugsDiseaseRelapsing-RemittingSettore MED/26Pregnancy planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideTeriflunomideNitrilesmedicineHumans030212 general & internal medicineAdverse effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosismedicine.diseaseSettore MED/26 - NEUROLOGIANeurologychemistryTolerabilityItalyMultiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis Relapsing-RemittingCrotonatesNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology
researchProduct

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

2015

Introduction Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation after NTZ discontinuation; (2) to evaluate predictors of reactivation risk, and (3) to compare the effect of different treatments in reducing this risk. Methods Data from 132 patients with MS followed-up for 2 years before NTZ treatment and 1 year after interruption were collected from two Italian MS centers and retrospectively evaluated. Results Overall, 72 of 132 patients (54.5%) had relapses af…

medicine.medical_specialtyNeurologyNatalizumab discontinuationDiseasePharmacologyMultiple sclerosisNatalizumabInternal medicineparasitic diseasesDisease reactivationmedicineMultiple sclerosiIn patientFirst-line therapieOriginal ResearchDisease reactivation; First-line therapies; Multiple sclerosis; Natalizumab discontinuation; Rebound; Second-line therapies; Neurology (clinical); NeurologyFirst-line therapiesReboundSecond-line therapiebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseDiscontinuationNeurologyTreatment strategyNeurology (clinical)businessSecond-line therapiesmedicine.drug
researchProduct

Common risk factors of three diseases.

1992

medicine.medical_specialtyNeurologybusiness.industryGeneral NeurosciencePublic healthAmyotrophic Lateral SclerosisMEDLINEParkinson DiseaseEnvironmental ExposureAlzheimer DiseaseRisk FactorsFamily medicineMedicineHumansNeurology (clinical)NeurosurgeryRisk factorbusinessNeuroradiologyItalian journal of neurological sciences
researchProduct

The capacity to consent to treatment in amyotrophic lateral sclerosis: a preliminary report

2020

Background: Facing the relentless worsening of their condition, ALS patients are required to make decisions on treatments and end-of-life care. A cognitive impairment showed to be a negative prognostic factor in ALS patients, perhaps affecting the ability to make informed decisions. Notwithstanding its crucial role, the capacity to consent to treatment (CCT) has never been evaluated in these patients. Objectives: To assess the CCT in an ALS cohort in comparison to a control group, and to study the effects of demographic and clinical variables on this high-level cognitive function. Methods: 102 ALS patients and 106 healthy controls (HC) were enrolled. CCT was assessed using the MacArthur Com…

medicine.medical_specialtyNeurologygenetic structuresDiseaseNeuropsychological TestsAffect (psychology)03 medical and health sciencesCognition0302 clinical medicinemedicineHumans030212 general & internal medicineAmyotrophic lateral sclerosisAmyotrophic lateral sclerosiDepression (differential diagnoses)Informed Consentbusiness.industryAmyotrophic Lateral SclerosisNeuropsychologyCognitionmedicine.diseaseeye diseases3. Good healthCognitive impairmentNeurologyCohortNeuropsychological Testsense organsNeurology (clinical)Cognition Disordersbusiness030217 neurology & neurosurgeryDecision-makingHumanClinical psychologyJournal of Neurology
researchProduct

Bisphosphonates and atherosclerosis: why?

2005

The increasing knowledge on bone calcification processes has revealed some similarities with vascular tissue, where calcifications of arteries and cardiac valves contribute to several cardiovascular problems, such as heart failure, systolic hypertension, and myocardial and peripheral ischemic disease. Bisphosphonates have been used extensively for over two decades for the treatment of diseases associated with excessive bone resorption, i.e., osteoporosis, osteolytic bone metastasis, hypercalcemia and Paget’s disease, by blocking osteoclastic function. Etidronate, pamidronate and clodronate has been shown to inhibit the development of experimental atherosclerosis, and proposed mechanisms fo…

medicine.medical_specialtyOsteoporosisMevalonic AcidApoptosisDisease030204 cardiovascular system & hematologyBone resorption03 medical and health sciences0302 clinical medicineRheumatologyCalcinosisInternal medicinemedicineHumansBone ResorptionFoam cell030203 arthritis & rheumatologyDiphosphonatesMolecular Structurebusiness.industryMacrophagesBone metastasisCalcinosismedicine.diseaseAtherosclerosisArterial calcificationEndocrinologyCholesterolHeart failureCancer researchbusinessLupus
researchProduct

Cardiovascular risk and events in polycystic ovary syndrome

2009

Young women with polycystic ovary syndrome (PCOS) present a high risk for cardiovascular disease because of the presence of abdominal obesity, insulin resistance and androgen excess. In addition, they present with endothelial dysfunction and early signs of atherosclerosis (increased carotid intima-media thickness and increased coronary calcium). However, the evidence of increased cardiovascular events during the postmenopausal age is relatively small, although some recent studies have indicated a slight increase in the severity of cardiovascular disease in women who had PCOS during their fertile age. The discrepancy between cardiovascular risk in young age and postmenopausal cardiovascular …

medicine.medical_specialtyPCOS Cardiovascular risk myocardial infarction stroke atherosclerosisSettore MED/09 - Medicina InternaDiseaseAndrogen ExcessSeverity of Illness IndexSettore MED/13 - EndocrinologiaInsulin resistanceRisk FactorsInternal medicinePrevalencemedicineHumansEndothelial dysfunctionAbdominal obesityEvidence-Based Medicinebusiness.industryHyperandrogenismObstetrics and GynecologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryPostmenopauseEndocrinologyPremenopauseCardiovascular DiseasesFemalemedicine.symptombusinessDyslipidemiaPolycystic Ovary SyndromeClimacteric
researchProduct

Efficacy of 12 weeks of proprioceptive training in patients with multiple sclerosis

2019

This pilot study aims to investigate if specific training protocol can improve the quality of life in people with multiple sclerosis through the improvement of some impaired ability like the balance. We enrolled in our project 20 subjects (age: 34,88 ± 4,45; height: 168,25 ± 8,66 cm; weight: 72,31 ± 17,28 kg) but only 5 completed the study. A proprioceptive training was administered for 12 weeks, 2 times a week, an hour for each session. At the beginning (T0) and at the end of the study (T1), static and dynamic balance parameters were tested. Statistical analyzes were performed using IBM SPSS Statistics 22.Changes in balance and strength between T0, T1 were evaluated using t Student test fo…

medicine.medical_specialtyPaired DataProprioceptionbusiness.industryForefootMultiple sclerosismedicine.diseaseNeurodegenerative diseaseGaitBaropodometryPhysical therapymedicineEducación Física y DeportivaProprioceptive trainingbusinessDynamic balanceProprioceptive training.StatisticBalance (ability)Dynamic balance
researchProduct